Why GLP-1 weight loss plateaus, and what the trials actually show

Key takeaways

• GLP-1 weight curves are steep then bend. STEP-1 (semaglutide 2.4 mg, 68 weeks) reached approximately -14.9 percent. SURMOUNT-1 (tirzepatide 15 mg, 72 weeks) reached approximately -20.9 percent. STEP-5 confirmed the nadir is typically reached by week 60 and is stable through week 104.
• The plateau is biological: receptor desensitization, adaptive thermogenesis (Fothergill 2016, Leibel 1995), and partial restoration of caloric intake.
• Higher-affinity or multi-receptor compounds (tirzepatide GLP-1+GIP, retatrutide GLP-1+GIP+glucagon, CagriSema GLP-1+amylin) reach lower nadirs but still plateau.
• Discontinuation produces weight regain: STEP-1 extension showed roughly two-thirds regain by week 120; SURMOUNT-4 showed similar. The drug is chronic-disease management, not a finite course.
• Three published levers can change the curve: dose escalation within label, multi-receptor combination strategies, and resistance training plus protein-forward eating during the active loss phase.

What the GLP-1 weight curve actually looks like

Public discussion treats GLP-1 weight loss as a steady decline, but the registration trials show something different. STEP-1 (semaglutide 2.4 mg weekly) reported a mean weight reduction of about 14.9 percent over 68 weeks, with most loss accruing in the first 40 to 60 weeks before flattening . SURMOUNT-1 (tirzepatide 5, 10, and 15 mg weekly) showed a similar shape, reaching roughly 20.9 percent at the 15 mg dose by 72 weeks before slowing .

STEP-5 extended semaglutide treatment to 104 weeks and demonstrated that weight nadir was generally reached between weeks 60 and 80, with weight stable thereafter through week 104; the curve does not continue to decline indefinitely . The plateau is reproducible across compounds, doses, populations, and trial designs, which is the first clue that biology is doing the bending, not behavior.

Named trial nadirs by compound

• Semaglutide 2.4 mg (STEP-1, 68 weeks): mean -14.9 percent body weight .
• Semaglutide 2.4 mg (STEP-5, 104 weeks): mean -15.2 percent, nadir typically by week 60 .
• Tirzepatide 15 mg (SURMOUNT-1, 72 weeks): mean -20.9 percent .
• Tirzepatide 15 mg (SURMOUNT-3, intensive lifestyle lead-in then drug, 88 weeks): mean -26.6 percent additional after lead-in .
• Retatrutide 12 mg (Phase 2, 48 weeks): mean -24.2 percent body weight; the trial was not long enough to characterize a plateau .
• CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg, REDEFINE-1, 68 weeks): mean -22.7 percent body weight .

The receptor side of the story

GLP-1 receptor agonists slow gastric emptying, blunt postprandial glucose excursions, and act on hypothalamic and brainstem circuits (arcuate nucleus POMC neurons, area postrema) that reduce appetite. Sustained agonist exposure shifts receptor density and downstream signaling. Preclinical work has documented homologous desensitization at the GLP-1 receptor, and the GIP component of dual agonists like tirzepatide adds a second pathway that may delay or partially offset that adaptation .

Higher-affinity or multi-receptor compounds push the curve further before bending. Tirzepatide (GLP-1 + GIP) reaches a lower nadir than semaglutide. Retatrutide (GLP-1 + GIP + glucagon triple agonist) reaches a lower nadir than tirzepatide in the published phase 2 data. The pattern is consistent with a model where the plateau is partly a ceiling on the appetite-suppression circuit being engaged at any given dose .

The energy expenditure side: adaptive thermogenesis

Weight loss of any kind reduces resting energy expenditure beyond what fat-free mass alone would predict, a phenomenon called adaptive thermogenesis. The Biggest Loser cohort follow-up (Fothergill 2016) characterized persistent metabolic adaptation at 6 years post-intervention, with resting metabolic rate roughly 500 kcal/day below predicted values . Earlier work by Leibel and colleagues demonstrated similar adaptation in inpatient overfeeding and underfeeding studies, suggesting that adaptive thermogenesis is a stable physiological response to negative energy balance .

The practical implication is that the calorie deficit shrinks as weight falls. If energy intake also drifts upward as appetite suppression partially desensitizes, the deficit collapses and the curve flattens. The plateau is the predictable equilibrium, not a failure of the drug.

What actually changes the curve

Three lever categories have published evidence behind them.

• Dose escalation within label, with attention to nausea and the FDA dosing-error guidance for compounded products . Higher doses delay the bend; the dose-response shape of SURMOUNT-1 is a clear demonstration .
• Combination strategies adding amylin signaling (CagriSema in REDEFINE-1) or glucagon-receptor activity (retatrutide in phase 2) extend weight loss beyond what monotherapy GLP-1 produces .
• Resistance training plus protein-forward eating during the active loss phase, which is mechanism-grounded but still being formally trialed against GLP-1 backdrops; existing trials have shown that adequate protein intake (>=1.2 g/kg) and resistance training preserve fat-free mass during caloric deficit independent of pharmacotherapy.

The discontinuation question: what happens off-drug

STEP-1 had a randomized withdrawal extension (STEP-1 OL): subjects who stopped semaglutide regained approximately two-thirds of the lost weight by week 120, with parallel changes in cardiometabolic risk markers . SURMOUNT-4 ran a similar withdrawal trial for tirzepatide and showed comparable regain after randomized discontinuation . The body re-establishes its previous setpoint when GLP-1 receptor activation stops; the plateau on drug is not a permanent reset of biology.

This is the mechanistic basis for the chronic-disease framing of obesity in the labeled indication: long-term therapy for chronic weight management, not a finite course.

What this means for people using these drugs

The plateau is information. It tells you the drug has reached the equilibrium your current dose, training, and intake support. It is not a verdict on adherence and it is not, by itself, a reason to escalate beyond label without a prescriber. The risk profile of compounded GLP-1 products is also different from labeled products, and the FDA has issued repeated cautions on dosing errors with compounded semaglutide and tirzepatide .

Related tools

• Tirzepatide dose calculator - Run tirzepatide-focused vial draw math.
• GLP-1 conversion calculator - Convert a GLP-1 mg dose to U-100 units and ml.
• GLP-1 ramp planner - Preview a linear educational dose-step table.
• Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.
• PK simulator overview - Public overview of the Pro pharmacokinetic simulator.
• Plateau analyzer overview - Public overview of the Pro plateau-pattern analyzer.